Human endothelial progenitor cells (EPCs) are circulating cells that exhibit a range of cell surface markers comparable to those found on vascular endothelial cells. They encompass primitive endothelial cells that possess enhanced angiogenic and vasculogenic characteristics. These primitive endothelial cells have the remarkable capacity to proliferate and undergo differentiation, ultimately maturing into functional endothelial cells. Human Endothelial Progenitor Cell from Ace Therapeutics can be expanded for up to 120 population doublings or 12 passages, providing ample material for experimentation. They express positive markers such as CD31, CD144, (VEGF)R2, CD146, CD73, CD105, and exhibit the uptake of acetylated low-density lipoprotein. Furthermore, AcceGen provides one million viable cells upon thawing of the frozen vial, which is shipped in dry ice to maintain cell integrity during transportation.

Human Neural Stem Cells (HNSC) are self-renewing, generated throughout an adult’s life via neurogenesis. These multipotent adult stem cells generate the main phenotype of the nervous system, differentiating into neurons, astrocytes, and oligodendrocytes. Ace Therapeutics's Human Neural Stem Cells-cortex region are cells derived from the cortex region of human brain (single donor). They are cryopreserved at first passage. Our HNSC stain positive for β-tubulin III, GFAP and oligodendrocyte marker O4 when cultured in Human Neural Differentiation Medium for 10 days. Cells are only guaranteed with the purchase of Ace Therapeutics's Media and Ace Therapeutics's Extra Cellular Matrix for appropriate cell culture, for 30 days from the date of shipment.

Human iPSC-derived Astrocytes from Ace Therapeutics is derived from integration-free, induced pluripotent stem cells (iPSCs) under fully defined growth conditions using a completely reproducible process.

Human CD34+ Hematopoietic Stem Cell from Bone Marrow (HHSC-BM) or Liver (HHSC-L) contain CD34+ progenitor cells that differentiate into all the various blood cell types. Cells are only guaranteed with the purchase of Ace Therapeutics's Media and Ace Therapeutics's Extra Cellular Matrix for appropriate cell culture, for 30 days from the date of shipment.

Human iPSC Line (Episomal, PBMC) from Ace Therapeutics was derived from human mesenchymal stromal cells (MSCs) by ectopic expression of OCT4, SOX2, KLF4, and L-MYC genes using episomal plasmids.

Human reprogrammed iPSC Cells established from endothelial progenitor cells that derived from peripheral blood.

Human iPSC-derived Brain Microvascular Endothelial Cells (iBMECs) from Ace Therapeutics are derived from integration-free induced pluripotent stem cell (iPSC) lines under a fully defined proprietary induction condition. iBMEC cells are compact cellular structures when plated as a monolayer in culture and express standard biomarkers such as ECadherin and ZO-1 using immunohistochemistry methods and transporter biomarkers such as ABCB1 (P-gp), ABCG2, ABCE1, HIF1A, CLDN5, GLUT1, LAT1, MCT1, TJP1, PDGFbeta, OCLN, SLC25A3, TFR1, and SLC25A5 using RT/qPCR methods. Each vial contains at least 1×10^6 cells per ml and is delivered frozen.

Human Bone Marrow CD133+ Stem/Progenitor Cells from Ace Therapeutics are isolated using positive immunomagnetic cell separation procedures from bone marrow. Capable of a high level of proliferation and a wide range of differentiation, transplantation of bone marrow CD133+ cell lines has been shown to not only induced multilineage human hematopoiesis through the CD34+ lineage but also induce regeneration of cell lines in vitro in multiple locations by differentiating into endothelial cells, neural cells, hepatocytes, osteoblasts, and myocytes, with the list of tissue types this cell can differentiate into gradually increasing.

CD34 is a well-known marker for primitive and bone marrow-derived progenitor cells, especially for hematopoietic and endothelial progenitors. CD34+ progenitor cells are suitable for a series of studies for directed differentiation into more committed types of blood cells and endothelial lineages. Immediately after isolation, the freshly prepared CD34+ progenitor cells are cryopreserved using a serum-free freezing medium. The majority of CD133+ cells also express CD34. Cord blood CD133+ cells are isolated using direct positive immunomagnetic selection for CD133+ cells. Ace Therapeutics offers CD34+ progenitor cells and CD133 cells in a phenotypically undifferentiated state.

The human iPSC line (episomal, CB) from Ace Therapeutics is a type of human induced pluripotent stem cell (iPSC) that was derived from human newborn cord blood (CB) mononuclear cells. The cells were reprogrammed into an embryonic-like pluripotent state using a method involving the introduction of OCT4, SOX2, KLF4, L-MYC, and Lin28 genes through episomal plasmids.